By Michael Susin

AstraZeneca PLC said Friday that U.S.'s Food and Drug Administration has approved the use of its combined treatment Imfinzi with Imjud for the treatment of patients with metastatic lung cancer.

The Anglo-Swedish pharma major said the approval was based on phase three study results, which showed a significant survival benefit of Imjudo added to Imfinzi and chemotherapy.

The trials data showed that the treatment presented a 23% reduction in the risk of death when compared with a range of chemotherapy options, it said.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

November 11, 2022 02:35 ET (07:35 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca